UK parallel traders claim L30M Cozaar/Hyzaar savings for NHS
As a result of parallel import competition, the UK's National Health service will save an estimated L30.2 million ($60.8 million) per year due to major price reductions for one drug alone, the British Association of European Pharmaceutical Distributors claims.
Merck Sharp & Dohme, the UK subsidiary of US drug major Merck & Co, has cut by nearly a third the price of its angiotensin receptor blocker Cozaar/Hyzaar (losartan), the UK's sixth most prescribed drug. The drug's patent was due to expire in Spain this year (Marketletter November 27, 2006) and parallel importers have attained a market share of up to 75% for products of the Cozaar range in the UK.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze